Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study

Overview of attention for article published in Ophthalmology, February 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Readers on

mendeley: 22 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 28,338 followers.

RT @AAOjournal: Phase 2/3 XIRIUS trial, cotoretigene toliparvovec (BIIB112/AAV8-RPGR) subretinal gene therapy for X-linked retinitis pigmen…

Phase 2/3 XIRIUS trial, cotoretigene toliparvovec (BIIB112/AAV8-RPGR) subretinal gene therapy for X-linked retinitis pigmentosa: did not meet primary endpoint. Improvements in mean microperimetry & low-luminescence visual acuity through 12 mo were s…

Ophthopedia Update: Assessment of Visual Function With Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study https://t.co/2DPAfaVXQM #Ophthalmology #ophthotwitter #eyecare https://t.co/dSEqoVKSUU

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.